HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (12) Citing Articles via Google Scholar Google Scholar Articles by LEE, T. H. Articles by PELLETIER, J. Search for Related Content PubMed PubMed Citation Articles by LEE, T. H. Articles by PELLETIER, J.

Functional characterization of WT1 binding sites within the human vitamin D receptor gene promoter

¹ Department of Biochemistry
² McGill Cancer Center, McGill University, Montreal, Quebec, Canada H3G 1Y6

The Wilms’ tumor suppressor gene, wt1, encodes a zinc finger transcription factor that can regulate gene expression. It plays an essential role in tumorigenesis, kidney differentiation, and urogenital development. To identify WT1 downstream targets, gene expression profiling was conducted using a cDNA array hybridization approach. We confirm herein that the human vitamin D receptor (VDR), a ligand-activated transcription factor, is a WT1 downstream target. Nuclear run on experiments demonstrated that the effect of WT1 on VDR expression is at the transcriptional level. Transient transfection assays, deletion mutagenesis, electrophoretic mobility shift assays, and chromatin immunoprecipitation assays suggest that, although WT1 is presented with a possibility of three binding sites within the VDR promoter, activation of the human VDR gene appears to occur through a single site. This site differs from a previously identified WT1-responsive site in the murine VDR promoter (Maurer U, Jehan F, Englert C, Hübinger G, Weidmann E, DeLucas HF, and Bergmann L. J Biol Chem 276: 3727–3732, 2001). We also show that the products of a Denys-Drash syndrome allele of wt1 inhibit WT1-mediated transactivation of the human VDR promoter. Our results indicate that the human VDR gene is a downstream target of WT1 and may be regulated differently than its murine counterpart.

vitamin D receptor; gene regulation; Wilms’ tumor

This article has been cited by other articles:

				H.-S. Kim, M. S. Kim, A. L. Hancock, J. C. P. Harper, J. Y. Park, G. Poy, A. O. Perantoni, M. Cam, K. Malik, and S. B. Lee Identification of Novel Wilms' Tumor Suppressor Gene Target Genes Implicated in Kidney Development J. Biol. Chem., June 1, 2007; 282(22): 16278 - 16287. [Abstract] [Full Text] [PDF]

				Y. Bor, J. Swartz, A. Morrison, D. Rekosh, M. Ladomery, and M.-L. Hammarskjold The Wilms' tumor 1 (WT1) gene (+KTS isoform) functions with a CTE to enhance translation from an unspliced RNA with a retained intron Genes & Dev., June 15, 2006; 20(12): 1597 - 1608. [Abstract] [Full Text] [PDF]

				L. A. Simpson, E. A. Burwell, K. A. Thompson, S. Shahnaz, A. R. Chen, and D. M. Loeb The antiapoptotic gene A1/BFL1 is a WT1 target gene that mediates granulocytic differentiation and resistance to chemotherapy Blood, June 15, 2006; 107(12): 4695 - 4702. [Abstract] [Full Text] [PDF]

				A. Kuhlmann, C. S. Haas, M.-L. Gross, U. Reulbach, M. Holzinger, U. Schwarz, E. Ritz, and K. Amann 1,25-Dihydroxyvitamin D3 decreases podocyte loss and podocyte hypertrophy in the subtotally nephrectomized rat Am J Physiol Renal Physiol, March 1, 2004; 286(3): F526 - F533. [Abstract] [Full Text]

				M. T. Discenza and J. Pelletier Insights into the physiological role of WT1 from studies of genetically modified mice Physiol Genomics, February 13, 2004; 16(3): 287 - 300. [Abstract] [Full Text] [PDF]

				T. H. Lee, S. Lwu, J. Kim, and J. Pelletier Inhibition of Wilms Tumor 1 Transactivation by Bone Marrow Zinc Finger 2, a Novel Transcriptional Repressor J. Biol. Chem., November 15, 2002; 277(47): 44826 - 44837. [Abstract] [Full Text] [PDF]